이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Amoy Diagnostics 관리

관리 기준 확인 2/4

Amoy Diagnostics' CEO는 Jiemin Luo, Jan2012 에 임명되었습니다 의 임기는 12.42 년입니다. 는 CN¥ 2.78M 가치에 해당하는 회사 주식의 0.038% 직접 소유합니다. 2.78M. 경영진과 이사회의 평균 재임 기간은 각각 12.4 년과 2.8 년입니다.

주요 정보

Jiemin Luo

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	12.5yrs
CEO 소유권	0.04%
경영진 평균 재임 기간	12.5yrs
이사회 평균 재임 기간	2.9yrs

최근 관리 업데이트

Recent updates

Amoy Diagnostics' (SZSE:300685) Upcoming Dividend Will Be Larger Than Last Year's

May 27

Earnings Report: Amoy Diagnostics Co., Ltd. Missed Revenue Estimates By 6.1%

Apr 24

Amoy Diagnostics (SZSE:300685) Could Easily Take On More Debt

Apr 18

What Amoy Diagnostics Co., Ltd.'s (SZSE:300685) 33% Share Price Gain Is Not Telling You

Mar 02

Is Amoy Diagnostics Co., Ltd. (SZSE:300685) Worth CN¥22.0 Based On Its Intrinsic Value?

Mar 01

CEO

Jiemin Luo (41 yo)

12.5yrs

테뉴어

CN¥676,500

보상

Mr. Jiemin Luo has been General Manager of Amoy Diagnostics Co., Ltd. and served its Deputy General Manager and Secretary of The Board of Directors since January 2012. He has been Non-Independent Director...

리더십 팀

이름	위치	테뉴어	보상	소유권
Ying Chen	CFO, Accounting Supervisor & Secretary to the Board of Directors	9.2yrs	CN¥872.70k	0.038% CN¥ 2.8m
Ruan Li	Deputy GM	15.9yrs	CN¥872.70k	0.039% CN¥ 2.8m
Frank Ron Zheng	Deputy GM & Director	2.9yrs	CN¥802.30k	데이터 없음
Huibin Zheng	Deputy General Manager	no data	CN¥694.40k	0.038% CN¥ 2.8m
Jiemin Luo	GM & Director	12.5yrs	CN¥676.50k	0.038% CN¥ 2.8m
Fei Luo	Deputy GM & Director	14.9yrs	CN¥755.80k	데이터 없음

12.5yrs

평균 재임 기간

46yo

평균 연령

경험이 풍부한 관리: 300685 의 관리팀은 노련하고 경험 (평균 재직 기간 12.4 년)입니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Ruan Li	Deputy GM	1.4yrs	CN¥872.70k	0.039% CN¥ 2.8m
Frank Ron Zheng	Deputy GM & Director	2.9yrs	CN¥802.30k	데이터 없음
Jiemin Luo	GM & Director	2.9yrs	CN¥676.50k	0.038% CN¥ 2.8m
Fei Luo	Deputy GM & Director	14.9yrs	CN¥755.80k	데이터 없음
Li-Mou Zheng	Chairman	16.4yrs	CN¥490.30k	데이터 없음
Hongyu Wang	Chairman of Supervisory Board	9.1yrs	데이터 없음	데이터 없음
Xin Huang	Non-Independent Director	2.9yrs	데이터 없음	데이터 없음
Wenjin Su	Independent Director	2.9yrs	데이터 없음	데이터 없음
Enhua Wang	Independent Director	2.9yrs	CN¥112.70k	데이터 없음
Qi Du	Non-Employee Supervisor	2.9yrs	데이터 없음	데이터 없음
Jie Huang	Non-Employee Supervisor	2.9yrs	데이터 없음	데이터 없음

2.9yrs

평균 재임 기간

46yo

평균 연령

경험이 풍부한 이사회: 300685 의 이사회는 경험(평균 재직 기간 2.8 년)으로 간주되지 않으므로 새 이사회가 필요합니다.

Amoy Diagnostics 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Amoy Diagnostics Co., Ltd., Annual General Meeting, May 13, 2024

Less than half of directors are independent

Amoy Diagnostics Co., Ltd., Annual General Meeting, Jun 20, 2022

High number of new directors

Recent updates

Amoy Diagnostics Co., Ltd. to Report First Half, 2024 Results on Jul 30, 2024

Amoy Diagnostics' (SZSE:300685) Upcoming Dividend Will Be Larger Than Last Year's

Dividend increased to CN¥0.15

Amoy Diagnostics Co., Ltd. Announces Cash Dividend on A Shares for the Year 2023, Payable on 30 May 2024

Earnings Report: Amoy Diagnostics Co., Ltd. Missed Revenue Estimates By 6.1%

Amoy Diagnostics (SZSE:300685) Could Easily Take On More Debt

Full year 2023 earnings: EPS exceeds analyst expectations

Amoy Diagnostics Co., Ltd., Annual General Meeting, May 13, 2024

Amoy Diagnostics Co., Ltd. (SZSE:300685) commences an Equity Buyback Plan for CNY 200 million worth of its shares, under the authorization approved on February 26, 2024.

Amoy Diagnostics Co., Ltd. to Report Q1, 2024 Results on Apr 23, 2024

Price target decreased by 7.6% to CN¥29.52

What Amoy Diagnostics Co., Ltd.'s (SZSE:300685) 33% Share Price Gain Is Not Telling You

Is Amoy Diagnostics Co., Ltd. (SZSE:300685) Worth CN¥22.0 Based On Its Intrinsic Value?

Now 24% overvalued

Investor sentiment improves as stock rises 20%

New minor risk - Share price stability

Amoy Diagnostics Co., Ltd. to Report Fiscal Year 2023 Results on Apr 16, 2024

Amoy Diagnostics Co., Ltd.(SZSE:300685) dropped from Shenzhen Stock Exchange Component Index

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Amoy Diagnostics Co., Ltd. to Report Q3, 2023 Results on Oct 24, 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Amoy Diagnostics Co., Ltd. to Report First Half, 2023 Results on Aug 01, 2023

Amoy Diagnostics Co., Ltd. Announces 2022 Final Profit Distribution Plan to Be Implemented (A Shares), Payment Date of 23 May 2023

Full year 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to CN¥35.47

Less than half of directors are independent

Consensus revenue estimates fall by 18%

Price target decreased to CN¥41.29

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Investor sentiment improved over the past week

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Amoy Diagnostics Co., Ltd., Annual General Meeting, Jun 20, 2022

Amoy Diagnostics Co., Ltd. Announces Dividend, Payable on May 31, 2022

Amoy Diagnostics Co., Ltd. Approves Dividend for 2021

Price target decreased to CN¥82.96

High number of new directors

Amoy Diagnostics Co., Ltd. Announces the Profit Distribution Proposal for 2021

Price target decreased to CN¥93.33

Full year 2021 earnings: EPS and revenues miss analyst expectations

Now 22% undervalued after recent price drop

Consensus EPS estimates fall by 15%

Full year 2021 earnings: EPS and revenues miss analyst expectations

Amoy Diagnostics Co., Ltd. (SZSE:300685) announces an Equity Buyback for CNY 200 million worth of its shares.

Amoy Diagnostics Co., Ltd. and PREMIA Holdings (HK) Limited Announces the Commercial Launch of the AmoyDx® Pan Lung Cancer PCR Panel in Japan

Third quarter 2021 earnings released: EPS CN¥0.29 (vs CN¥0.21 in 3Q 2020)

Price target increased to CN¥105

Second quarter 2021 earnings released: EPS CN¥0.30 (vs CN¥0.24 in 2Q 2020)

Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd., and Precision Medicine Asia Co., Ltd. Announce the Approval of AmoyDx Pan Lung Cancer PCR Panel

Full year 2020 earnings released: EPS CN¥0.82 (vs CN¥0.63 in FY 2019)

New 90-day low: CN¥67.96

Amoy Diagnostics Co., Ltd. to Report Fiscal Year 2020 Results on Apr 13, 2021

New 90-day high: CN¥92.11

New 90-day high: CN¥87.26

New 90-day low: CN¥71.91

New 90-day low: CN¥72.29

Third quarter earnings released

New 90-day high - CN¥88.26

New 90-day high - CN¥79.53

Amoy Diagnostics Co., Ltd. to Report First Half, 2020 Results on Jul 28, 2020

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령